|Mr. John Stewart Sharman B Ec, CA, M.App.Fin||Chief Exec. Officer||526.8k||N/A||1966|
|Mr. Salesh Balak BA, CA||CFO & Company Sec.||300.69k||N/A||1969|
|Mr. Nicholas Bliesner||Head of Operations||N/A||N/A||N/A|
|Mr. Luke Cossins||Head of R&D||N/A||N/A||N/A|
|Ms. Ann Chew B.Com., CPA||Head of People Strategy & Culture||N/A||N/A||N/A|
Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips; and distributes Siemens' Xprecia Stride Coagulation Analyzer, a test used to monitor the effect of the anticoagulant therapy warfarin. The company also manufactures and distributes Sentia SO2 test strips; and distributes Sentia Analyzer for the use in measurement of free SO2 levels in post-fermentation wine. In addition, it offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a biosensor strip and a meter to be used for the detection and monitoring of diabetes in animals. Universal Biosensors, Inc. was incorporated in 2001 and is headquartered in Rowville, Australia.
Universal Biosensors, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.